Back to top
more

Loxo Oncology, Inc. (LOXO)

(Delayed Data from NSDQ)

$234.66 USD

234.66
NA

0.00 (0.00%)

Updated Feb 14, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[LOXO]

Reports for Purchase

Showing records 1 - 15 ( 15 total )

Industry: Medical - Drugs

Record: 1

01/07/2019

Company Report

Pages: 7

Loxo to be Acquired by Eli Lily for $8 billion.

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

11/28/2018

Company Report

Pages: 9

What Does IFS Expect from Larotrectinib Now That It Is FDA Approved?

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

11/08/2018

Company Report

Pages: 8

Loxo Oncology Reports Financial Results of Third Quarter and Updates Drug Development

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for LOXO

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

10/08/2018

Company Report

Pages: 7

Updated Thyroid Cancer Data for LOXO-292 Looks Good, Raising Our Rating to Outperform

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

08/09/2018

Company Report

Pages: 7

Loxo Oncology Reports 2Q2018 Financial Results - Our Takeaways

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

06/04/2018

Company Report

Pages: 12

ASCO Data for RET Inhibitor Looks Strong But Stock Looks Ahead of Itself

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

05/08/2018

Company Report

Pages: 7

Reports 1Q2018 Financial Results - Our Takeaways

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

03/05/2018

Company Report

Pages: 7

Reports Q4 and FY2017 Financial Results

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

02/26/2018

Company Report

Pages: 6

Updated Estimates Ahead of Loxo Oncology?s Q4 and FY2017 Financial Results

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

11/14/2017

Company Report

Pages: 9

Loxo Oncology Partners with Bayer AG to sell Larotrectinib, Raising our Rating and Target Price

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

11/02/2017

Company Report

Pages: 6

Reports 3Q2017 Financial Results In-Line with Our Expectations

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

10/30/2017

Company Report

Pages: 10

Updating our estimates for the September quarter

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

10/18/2017

Company Report

Pages: 10

Final Response Rates from Pivotal Dataset for Larotrectinib Look Great - Raising Target Price

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

08/08/2017

Company Report

Pages: 6

Reports 2Q2017 Financial Results

Provider: IFS Securities, Inc.

Analyst: BOUCHEY D

Price: 25.00

Research Provided by a Third Party